Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Standard Bupivacaine in Thoracic Surgery
NCT03508830Phase 3Completed
- Sponsor
- University of California, San Francisco
- Start
- Dec 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Average Daily In-Hospital Use of Opioids at 1 week. Started Dec 2018; status: completed.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03508830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508830.